iECURE emerges with $50M to search for ‘holy grail’ and ‘untapped frontier’ of gene editing

James M. Wilson, MD, PhD

iECURE is emerging from stealth with $50 million and a mission to go after the “holy grail” of gene editing with an in vivo approach that is mutation agnostic.

The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at the University of Pennsylvania.

Read more in Fierce BioTech

Skip to content